Faeth Therapeutics, Inc.

SEC 4 · Filed

0002137706-26-000003Accepted

Applies to the EDGAR acceptance time.

Other time zone
Insider transactionsEvent date Jun 15, 2026

Conversion by Hahn Stephen M.

Security
Series B Preferred Stock
Code
C
Shares
44.76Reported 44.763
Price per share
Unreported
Structured facts
{
  "code": "C",
  "date": "2026-06-15",
  "direction": "D",
  "exercise_price": null,
  "expiration": null,
  "footnotes": {
    "F1": "Subject to certain conditions set forth in the Certificate of Designation of Preferences, Rights and Limitations of the Series B Preferred Stock, each share of Series B Preferred Stock is convertible into 1,000 shares of the Issuer\u0027s Common Stock and has no expiration date.",
    "F2": "Pursuant to February 17, 2026 Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Sapphire First Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Issuer (\"First Merger Sub\"), Sapphire Second Merger Sub, LLC, a Delaware limited liability company and wholly owned subsidiary of the Issuer (\"Second Merger Sub\"), Faeth Holdings Therapeutics, Inc. (\"HoldCo\") and Faeth Therapeutics, LLC, a Delaware limited liability company and wholly owned subsidiary of HoldCo (\"Faeth\"), First Merger Sub merged with and into HoldCo, with HoldCo surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, HoldCo merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, the \"Merger\").",
    "F3": "Footnote continued: Upon the closing of the Merger, shares of outstanding common stock of HoldCo were converted into the right to receive shares of the Issuer\u0027s Series B Preferred Stock."
  },
  "owners": [
    {
      "cik": "0002137706",
      "name": "Hahn Stephen M.",
      "roles": [
        "director"
      ],
      "title": null
    }
  ],
  "ownership": "D",
  "post_shares": "0",
  "price": null,
  "row": 2,
  "rule_10b5_1": "0",
  "security": "Series B Preferred Stock",
  "shares": "44.763",
  "table": "II",
  "underlying_security": "Common Stock",
  "underlying_shares": "44763"
}
Insider transactionsEvent date Jun 12, 2026

Grant, award or other acquisition by Hahn Stephen M.

Security
Stock Option (right to buy)
Code
A
Shares
25,000
Price per share
0.00
Structured facts
{
  "code": "A",
  "date": "2026-06-12",
  "direction": "A",
  "exercise_price": "13",
  "expiration": "2036-06-11",
  "footnotes": {
    "F4": "The shares subject to the option vest and become exercisable in 36 equal monthly installments over a three year period such that the option is fully vested on the third anniversary of the date of grant, or June 12, 2029, subject to the Reporting Person\u0027s continuous service with the Issuer as of each such vesting date."
  },
  "owners": [
    {
      "cik": "0002137706",
      "name": "Hahn Stephen M.",
      "roles": [
        "director"
      ],
      "title": null
    }
  ],
  "ownership": "D",
  "post_shares": "25000",
  "price": "0",
  "row": 1,
  "rule_10b5_1": "0",
  "security": "Stock Option (right to buy)",
  "shares": "25000",
  "table": "II",
  "underlying_security": "Common Stock",
  "underlying_shares": "25000"
}
Insider transactionsEvent date Jun 15, 2026

Conversion by Hahn Stephen M.

Security
Common Stock
Code
C
Shares
44,763
Price per share
Unreported
Structured facts
{
  "code": "C",
  "date": "2026-06-15",
  "direction": "A",
  "exercise_price": null,
  "expiration": null,
  "footnotes": {
    "F1": "Subject to certain conditions set forth in the Certificate of Designation of Preferences, Rights and Limitations of the Series B Preferred Stock, each share of Series B Preferred Stock is convertible into 1,000 shares of the Issuer\u0027s Common Stock and has no expiration date.",
    "F2": "Pursuant to February 17, 2026 Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Sapphire First Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Issuer (\"First Merger Sub\"), Sapphire Second Merger Sub, LLC, a Delaware limited liability company and wholly owned subsidiary of the Issuer (\"Second Merger Sub\"), Faeth Holdings Therapeutics, Inc. (\"HoldCo\") and Faeth Therapeutics, LLC, a Delaware limited liability company and wholly owned subsidiary of HoldCo (\"Faeth\"), First Merger Sub merged with and into HoldCo, with HoldCo surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, HoldCo merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, the \"Merger\").",
    "F3": "Footnote continued: Upon the closing of the Merger, shares of outstanding common stock of HoldCo were converted into the right to receive shares of the Issuer\u0027s Series B Preferred Stock."
  },
  "owners": [
    {
      "cik": "0002137706",
      "name": "Hahn Stephen M.",
      "roles": [
        "director"
      ],
      "title": null
    }
  ],
  "ownership": "D",
  "post_shares": "44763",
  "price": null,
  "row": 1,
  "rule_10b5_1": "0",
  "security": "Common Stock",
  "shares": "44763",
  "table": "I",
  "underlying_security": null,
  "underlying_shares": null
}